Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05593640

Thromboxane A2 and Osteoarthritis

TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de NICE

Nice, 06003, France

Location status: Recruiting

Location contact

Amri ez Zoubir

CONTACT

Christian ROUX

CONTACT

[email protected]

+33492035491

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • presence of knee osteoarthritis with effusion, , no inflammatory disease

Exclusion criteria

  • anticoagulant treatment
  • inflammatory disease

Treatment and study plan

Biological Samples

Other

blood and synovial liquid will be sampled

Primary outcomes

  1. to look for correlation between the rate of throboxane and the grade of osteoarthritis

    Time frame: 6 months

    kellgren and lawrence classification

Study contacts

Contact information is provided by the study sponsor or research team.

Christian ROUX, MD, PhD

CONTACT

[email protected]

+33492035491

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Collaborators

  • French Society of Rheumatology

Registry information

Official study title

Throboxane Effect on Chondrocytes; Role in Osteoarthritis

Important dates

Study start
2022
Primary completion
2023
Study completion
2027
First posted
Oct 25, 2022
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.